<DOC>
	<DOCNO>NCT01598857</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability blisibimod take methotrexate induction remission ANCA-Associated Small Vessel Vasculitis .</brief_summary>
	<brief_title>BIANCA-SC : A Study Efficacy , Safety , Tolerability Blisibimod Addition Methotrexate During Induction Remission Subjects With ANCA-Associated Small Vessel Vasculitis</brief_title>
	<detailed_description />
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Microscopic Polyangiitis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>1 . 18 year age old ( male female ) . 2 . Granulomatosis polyangiitis ( GPA , Wegener 's granulomatosis ) microscopic polyangiitis ( MPA ) accord definition American College Rheumatology Chapel Hill Consensus Conference . 3 . Active GPA MPA disease screen . 4 . Positive either PR3ANCA MPOANCA screen . 5 . Subject willing initiate corticosteroid methotrexate ( MTX ) already corticosteroids and/or MTX baseline . 6 . Clinical intention prescribe MTX therapy treatment GPA MPA . 1 . Diagnosed Churg Strauss syndrome . 2 . Severe GPA MPA disease would conventionally treat cyclophosphamide . 3 . Nursing pregnant . 4 . Active systemic infection deepspace infection . 5 . Active hepatitis B , active hepatitis C document history HIV , hepatitis B , hepatitis C. 6 . Liver disease . 7 . History document antiglomerular basement membrane ( GBM ) disease . 8 . Malignancy within past 5 year . 9 . History active tuberculosis ( TB ) history TB infection . 10 . Anemia , neutropenia , thrombocytopenia . 11 . Serum creatinine level great 2.5 mg/dL . 12 . Prior administration Bcell modulate therapy rituximab . 13 . Subject yet complete least 3 month 5 halflives ( whichever longer ) since end investigational study . 14 . History congenital immunodeficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>granulomatosis polyangiitis</keyword>
	<keyword>microscopic polyangiitis</keyword>
	<keyword>anti-neutrophil cytoplasmic antibody</keyword>
	<keyword>ANCA-associated vasculitis</keyword>
	<keyword>Wegener Granulomatosis</keyword>
</DOC>